Incretin GPCR/CRE Reporter Cell Lines
Obesity and Type 2 Diabetes (T2D) are tightly linked to cardiovascular disease, liver dysfunction, and neurodegenerative disorders such as Alzheimer’s disease and cognitive decline. Incretin-based therapies, including GLP-1 receptor (GLP-1R) agonists, GIPR co-agonists, and Amylin receptor modulators, have transformed metabolic disease treatment while demonstrating potent neuroprotective mechanisms in emerging clinical studies, such as liraglutide, a long-acting GLP-1 analog reported to reduce brain atrophy and slow cognitive decline in Alzheimer’s disease.
Signosis provides an assay-ready platform of GPCR/CRE Luciferase Reporter Stable Cell Lines engineered for high-sensitivity quantification of receptor-driven 𝐺𝛼𝑠–cAMP–CREB signaling. These cell models enable high-throughput screening (HTS) of single, dual ("twincretin"), and triple ("tri-agonist") receptor agonists across metabolic and neuro-focused drug pipelines.
Key Features & Research Applications
-
Metabolic Drug Discovery: Benchmark single-, dual- ("twincretin"), and multi-agonist candidates (e.g., Tirzepatide, Retatrutide mimetics) for glycemic control and weight management.
-
Oral & Small-Molecule Modulators: Screen non-peptide oral GLP-1R agonists (e.g., Danuglipron, Orforglipron) and amylin mimetics with high reproducibility.
-
Incretin-Driven Neuroprotection: Evaluate GLP-1 analogs (e.g., Liraglutide, Semaglutide) linked to reduced neuroinflammation and memory preservation.
-
Biased Signaling & Receptor Variants: Profile natural genetic variants (A416T, E354Q) and desensitization-resistant mutants (C-tail S/T→A) to isolate G-protein vs. 𝛽-arrestin pathways.
-
Assay-Ready HTS Compatibility: Validated for 96-well and 384-well formats with high signal-to-background ratios
Principle
Signosis GPCR Reporter Stable Cell Lines convert biological receptor activation into quantitative luminescent output:
-
Ligand Binding: Agonist engages target GPCR (GLP-1R, GIPR, or CTR/RAMP3).
-
cAMP Surge: Gα_s coupling stimulates Adenylyl Cyclase to boost intracellular cAMP.
-
CREB Activation: Elevated cAMP drives PKA phosphorylation of CREB at Ser133.
-
Reporter Expression: Phospho-CREB binds CRE promoters, driving Firefly Luciferase expression.
-
Luminescent Readout: Signal intensity directly measures functional potency (EC50/IC50).
Ligand binding to GLP1R, GIPR, or the CTR-RAMP3 complex activates Gs-coupled signaling, leading to increased cAMP, PKA activation, and CRE phosphorylation. Phospho-CREB drives transcription of a CRE-luciferase reporter, producing light via firefly luciferase.
Metabolic & Incretin Reporter Lines
GLP-1R Reporter Cell Lines
GIPR Reporter Cell Lines
Name | SKU | Price (USD) |
|---|---|---|
GIPR/CRE Luciferase Reporter HEK293 Stable Cell Line | SL-6002 | $3,870.00 |
GIPR (E354Q)/CRE Luciferase Reporter HEK293 Stable Cell Line SL-6002-2 | SL-6002-2 | $3,870.00 |
Amylin3 Reporter Cell Lines
Name | SKU | Price (USD) |
|---|---|---|
Amylin3/CRE Luciferase Reporter HEK293 Stable Cell Line (2 vials) | SL-6003 | $3,870.00 |
Benefits
High Induction
Over 100x Induction delivers clear, measurable responses for confident data interpretation.
Mycoplasma free
Rigorously screened to ensure clean, contamination-free cultures for reliable results.
Ligand-Responsive Readout
Uses the cAMP luciferase system to give a strong, measurable signal only when a ligand activates the receptor.
Mechanism-Focused Research
Helps researchers better understand how specific GIPR isoforms function in different pathways or diseases.
Ready to Use
Stable Cell Lines are immediately ready to use — no extra transfections or optimization needed.
Isoform-Specific Detection
Designed to measure the activity of GPCR, avoiding cross-reactivity seen in traditional assays.
Stable and Reproducible
Stably integrated reporter constructs ensure reproducible performance without the need for repeated transfections.
Fully Validated Performance
Each cell line is tested for correct receptor expression, ligand response, and antibiotic selection.
Fast and Easy Compound Screening
Compatible with both high-throughput and common assay formats, making them ideal for testing drugs or compounds that target GPCR receptors.
Improved Accuracy
Focuses on the receptor’s ligand-binding domain (LBD) instead of the shared DNA-binding region for more precise results.
Broad Agonist Responsiveness
The cell line is functionally validated to respond to both peptide and non-peptide agonists.
We offer a highly sensitive Firefly Luciferase Substrate, which can accurately measure firefly luciferase activity in cells.
FAQ
Q: How does the reporter system work?
A: Upon ligand binding, the target GPCR activates the Gs–cAMP pathway, leading to phosphorylation of CREB. Activated CREB binds to CRE elements upstream of the firefly luciferase reporter gene, producing a bright, dose-dependent luminescent signal proportional to receptor activation.
Q: What ligands can be used to validate these assays?
A: These cell lines respond strongly to native peptide hormones (GLP-1, GIP, Amylin), synthetic peptide analogs (Exendin-4, Liraglutide, Semaglutide, Tirzepatide, Retatrutide), and small-molecule oral agonists (e.g., Danuglipron).
Q: What is the benefit of testing the GLP-1R (C-tail S/T→A) mutant line?
A: By blocking C-terminal serine/threonine phosphorylation, this line minimizes receptor internalization and desensitization driven by 𝛽-arrestin, allowing researchers to isolate G-protein (cAMP)-biased activity.
Q: What is the stability of these cell lines over extended culture?
A: Antibiotic selection maintains stable receptor and reporter co-expression over 20–25+ continuous passages without signal decay.
Q: Do you offer custom cell line engineering?
A: Yes. Signosis routinely develops custom co-expression models (such as dual GLP-1R + GIPR or GLP-1R + Glucagon Receptor lines) and custom host cell backgrounds for specialized screening programs. We also provide custom screening services and can run assays for you.
